Axenya is a technology company.
Axenya is a corporate health management company that utilizes data intelligence to provide effective health solutions, aiming to reduce costs and improve employee well-being.
Axenya has raised $3.0M across 1 funding round.
Axenya has raised $3.0M in total across 1 funding round.
Axenya is a São Paulo, Brazil-based health tech company founded in 2020 that builds an AI-driven platform for orchestrating corporate healthcare.[1][2] It connects companies, employees, insurers, and healthcare providers through LifeVault—an interoperable data lake for clinical, operational, and administrative data—and Axenya IQ, a predictive AI and GenAI engine that anticipates risks, suggests interventions, and optimizes care journeys.[1][2] Serving large enterprises, Axenya solves fragmented corporate health management by reducing costs (e.g., 22% year-over-year drop, 50% below-market medical inflation) and improving outcomes for high-risk patients via predictive prevention, especially for chronic conditions like heart rate and blood pressure monitoring.[2][6] In August 2025, it raised $12 million in Series A funding led by Canary and co-led by Indicator Capital, following $6.8 million in prior rounds, to fuel commercial expansion and tech advancements.[1][2]
Axenya was founded in 2020 by Mariano Garcia-Valiño, who serves as CEO, amid Brazil's complex corporate healthcare landscape where traditional brokers fail to integrate stakeholders effectively.[1][2] Garcia-Valiño's vision emerged from recognizing the need for data intelligence to transform systemic inefficiencies, combining cutting-edge AI with a business model that reshapes healthcare delivery.[2] Early traction came from proven client results, such as 1,500 basis points lower loss ratios and 40% expense reductions for high-risk patients, building on prior funding from Patria High Growth, Big_Bets, and Zentynel.[2] The 2025 Series A marked a pivotal moment, validating its approach and enabling scale in Latin America's growing health tech market.[1]
Axenya rides the wave of AI-powered digital health transformation, particularly in managing chronic conditions amid rising corporate healthcare costs in Latin America.[3][6] Timing aligns with post-pandemic demand for predictive prevention and data interoperability, fueled by GenAI advancements and biomarker connectivity.[1][2] Market forces like Brazil's high medical inflation and fragmented systems favor its model, positioning it to influence the ecosystem by lowering barriers for insurers and providers while enabling enterprises to retain talent through better health outcomes.[2] As a leader in LatAm health tech, it exemplifies how regional VCs like Canary and Indicator Capital are backing deep-tech to bridge global AI trends with local needs.[1]
Axenya is poised for rapid scaling post-Series A, prioritizing commercial growth in Brazil and potentially LatAm expansion via strengthened channels and AI enhancements.[1][2] Trends like GenAI maturation, connected health devices, and employer-focused wellness will amplify its edge, especially as chronic care demands grow.[3][6] Its influence may evolve from cost-cutter to ecosystem orchestrator, potentially attracting Series B interest if it sustains 20-50% efficiency gains. This positions Axenya as a benchmark for AI reshaping corporate health, delivering the structural change Garcia-Valiño envisioned from day one.[2]
Axenya has raised $3.0M in total across 1 funding round.
Axenya's investors include DGF Investimentos, Igah Ventures.
Axenya has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2021 | $3.0M Seed | DGF Investimentos, Igah Ventures |